Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

FDA Backs Approval of Abbott's Humira for New Use

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/28/2012 | 10:06pm CEST

WASHINGTON--A federal advisory panel backed the use of an Abbott Laboratories (>> Abbott Laboratories) drug, Humira, as a treatment for patients with inflammatory bowel disease, saying many patients would benefit from treatment with the product.

Abbott is seeking expanded approval from the U.S. Food and Drug Administration for its anti-inflammatory drug Humira to treat ulcerative colitis. Humira, which had almost $8 billion in annual sales last year, currently is approved to treat rheumatoid arthritis, Crohn's Disease and other inflammatory conditions.

The drug was reviewed Tuesday by the FDA's gastrointestinal drugs advisory committee, which is made up of non-FDA medical experts. The panel voted 15 to 2 on a question that asked whether "the expected benefits outweigh the known and potential risks of Humira" for the treatment of certain patients with ulcerative colitis.

The vote amounts to a recommendation that the FDA approve the product. The FDA usually follows the advice of its panels but is not required to. The FDA declined to approve Humira for colitis last year and asked the company for additional information. The agency also said it would seek the advice of an advisory panel.

Abbott studied Humira in two clinical trials involving more than 1,000 patients. Both studies met goals showing Humira improved rates of disease remission compared to a placebo in people with colitis, an inflammatory bowel disease that causes pain, diarrhea and other symptoms. Patients in the studies also were being treated with older commonly used drugs for colitis including steroids.

Although the FDA agreed that the studies met their goals, the agency questioned whether the difference in remission rates of less than 10% between the Humira groups and placebo groups was "clinically meaningful." The studies showed about 17% to 19% of patients being treated with Humira achieved disease remission at eight weeks compared to about 9% of patients being treated with a placebo, according to the FDA. After one year of treatment the results were similar.

"The central issue is whether the applicant has adequately demonstrated and provided evidence of benefit sufficient to conclude that the benefit outweighs the risks of Humira for [ulcerative colitis]," the FDA said in a background memo prepared for the advisory committee meeting.

However, the majority of the panel disagreed, voting 15 to 1 saying that the differences between the drug and placebo groups were clinically meaningful.

Abbott officials and doctors who spoke on behalf of the company during the panel meeting said many patients with colitis don't respond well to currently available treatments, which also include Johnson & Johnson's (>> Johnson & Johnson) Remicade, and need an additional option. The company proposed stopping treatment in patients who don't respond to the drug after eight weeks of treatment.

Write to Jennifer Corbett Dooren at jennifer.corbett@dowjones.com

(CORRECTION: This item was corrected to show that the vote tally was 15 to 2. The original incorrectly stated 12 to 2 in the third paragraph.)

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Abbott Laboratories, Johnson & Johnson
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBOTT LABORATORIES
03:00p ABBOTT LABORATORIES PAKISTAN : Financial results of Abbott Laboratories Limited ..
08/18 ABBOTT LABORATORIES : North west london pathology and abbott partner for diagnos..
08/18 ABBOTT LABORATORIES : Announces extension of cash tender offer for all outstandi..
08/17 ABBOTT LABORATORIES : ' Trademark Application for "IBIS T5000" Filed
08/17 ABBOTT LABORATORIES : ' Trademark Application for "SIMILAC" Filed
08/17 ABBOTT LABORATORIES : Trademark Application for "LIBRE" Filed by Abbott Laborato..
08/16 Seven charged in U.S. insider trading ring
08/15 ABBOTT LABORATORIES : Sources Sought Notice - Maintenance and Software Support/U..
08/15 ABBOTT LABORATORIES : North West London Pathology and Abbott Partner for Diagnos..
08/15 ABBOTT LABORATORIES : Announces extension of cash tender offer for all outstandi..
More news
News from SeekingAlpha
08/17 Premarket analyst action - healthcare
08/16 GETTING DEFENSIVE : Buying Abbott Laboratories And Dominion Energy
08/15 Abbott Diagnostics lands $252M managed equipment contract in Britain
08/15 JOHNSON & JOHNSON : After Rising 15% This Year, What's Next?
08/14 Mylan Suffers From Jet Lag
Financials ($)
Sales 2017 26 470 M
EBIT 2017 5 762 M
Net income 2017 2 348 M
Debt 2017 14 982 M
Yield 2017 2,20%
P/E ratio 2017 44,79
P/E ratio 2018 27,33
EV / Sales 2017 3,77x
EV / Sales 2018 3,49x
Capitalization 84 683 M
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 54,9 $
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Miles D. White Chairman & Chief Executive Officer
Brian B. Yoor Chief Financial Officer & Executive VP-Finance
Roxanne Schuh Austin Independent Director
Jim Farrell Independent Director
Samuel C. Scott Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES26.89%84 683
JOHNSON & JOHNSON15.12%355 979
NOVARTIS7.69%216 915
ROCHE HOLDING LTD.3.78%216 699
PFIZER0.59%194 554
MERCK AND COMPANY4.45%167 705